Publicaciones en colaboración con investigadores/as de Université Catholique de Louvain (59)

2024

  1. The science of micronutrients in clinical practice – Report on the ESPEN symposium

    Clinical Nutrition

2023

  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267

  2. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

    The Lancet, Vol. 401, Núm. 10370, pp. 49-59

  3. Tactile expectancy modulates occipital alpha oscillations in early blindness

    NeuroImage, Vol. 265

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  3. Human genetic and immunological determinants of critical COVID-19 pneumonia

    Nature, Vol. 603, Núm. 7902, pp. 587-598

  4. Nutritional management of individuals with obesity and COVID-19: ESPEN expert statements and practical guidance

    Clinical Nutrition, Vol. 41, Núm. 12, pp. 2869-2886

  5. Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection

    JAMA Cardiology, Vol. 7, Núm. 2, pp. 159-166

  6. Strain-to-strain variability among Staphylococcus aureus causing prosthetic joint infection drives heterogeneity in response to levofloxacin and rifampicin

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 12, pp. 3265-3269

2021

  1. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline

    Leukemia, Vol. 35, Núm. 11, pp. 3295-3298

  2. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

    ESMO Open, Vol. 6, Núm. 5

  3. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease

    Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297

  4. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study

    European Urology, Vol. 80, Núm. 4, pp. 497-506

  5. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

    The Lancet Infectious Diseases, Vol. 21, Núm. 9, pp. 1313-1323

  6. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  7. Integrative transnational analysis to dissect tuberculosis transmission events along the migratory route from Africa to Europe

    Journal of travel medicine, Vol. 28, Núm. 4

  8. MPL S505C enhances driver mutations at W515 in essential thrombocythemia

    Blood Cancer Journal

  9. Socioeconomic disparities in suicide: Causation or confounding?

    PLoS ONE, Vol. 16, Núm. 1 January

  10. Vision, challenges and opportunities for a plant cell atlas

    eLife, Vol. 10